Latest Breaking News On - Therapy designation - Page 2 : comparemela.com

FDA grants Priority Review to Roche's inavolisib for

Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional.

NRX-101: First Antidepressant to Lower Suicidality in Bipolar Depression

Unlike approved antidepressant drugs which have warnings on their labels stating they may increase the suicide risk, NRX-101 demonstrates meaningful reductions in suicidality.

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

28.05.2024 - BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological . Seite 1

Baystreet.ca - Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference

USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 .

USA News Group: Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More